Immunocore (NASDAQ:IMCR) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• Immunocore shares moved above their 200-day moving average, reaching $32.00 and last trading at $31.96, up 2.2%. The stock’s 50-day moving average was $32.66, compared with $31.83 for its 200-day average.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $56.38. Recent targets included $43 from Morgan Stanley and $50 from JPMorgan, though some analysts maintain neutral or hold ratings.
• The company reported a quarterly loss of $0.02 per share, missing expectations by $0.01. Institutional investors and hedge funds own 84.5% of the stock, while Immunocore’s lead product is KIMMTRAK, an approved treatment for certain patients with metastatic uveal melanoma.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $31.83 and traded as high as $32.00. Immunocore shares last traded at $31.96, with a volume of 314,115 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Morgan Stanley set a $43.00 price target on Immunocore in a report on Friday, August 7th. JPMorgan Chase & Co. initiated coverage on Immunocore in a research report on Friday, August 21st. They set an "overweight" rating and a $50.00 target price on the stock. Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a report on Tuesday, July 28th. Mizuho lifted their target price on Immunocore from $34.00 to $35.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Immunocore in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.38.

Immunocore Stock Up 2.2%

The business has a 50-day moving average price of $32.66 and a two-hundred day moving average price of $31.83. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -86.38 and a beta of 0.81.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). On average, sell-side analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post 0.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Rockefeller Capital Management L.P. purchased a new stake in Immunocore in the 4th quarter valued at $47,000. GAMMA Investing LLC lifted its position in shares of Immunocore by 202.8% during the second quarter. GAMMA Investing LLC now owns 1,920 shares of the company's stock valued at $61,000 after purchasing an additional 1,286 shares in the last quarter. Juncture Wealth Strategies LLC bought a new position in shares of Immunocore during the third quarter valued at about $207,000. denkapparat Operations GmbH bought a new position in shares of Immunocore during the second quarter valued at about $209,000. Finally, Headlands Technologies LLC purchased a new position in Immunocore during the second quarter worth about $290,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company's lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.